Pitrilysin metallopeptidase 1 also known as presequence protease, mitochondrial (PreP) and metalloprotease 1 (MTP-1) is an enzyme that in humans is encoded by the PITRM1gene.[5][6][7] It is also sometimes called metalloprotease 1 (MP1).PreP facilitates proteostasis by utilizing an ~13300-A(3) catalytic chamber to degrade toxic peptides, including mitochondrial presequences and β-amyloid.[8] Deficiency of PreP is found associated with Alzheimer's disease. Reduced levels of PreP via RNAi mediated knockdown have been shown to lead to defective maturation of the protein Frataxin.[9]
PreP is a 117 kDa M16C enzyme that is widely expressed in human tissues.[10] PreP is composed of PreP-N (aa 33-509) and PreP-C (aa 576-1037) domains, which are connected by an extended helical hairpin (aa 510-575). Its structure demonstrates that substrate selection by size-exclusion is a conserved mechanism in M16C proteases.[8]
Function
PreP is an Zn2+-dependent and ATP-independent metalloprotease, it does not select substrates on the basis of post-translational modifications or embedded degradation tags.[11][12][13] Instead, it uses a negatively charged catalytic chamber to engulf substrates peptides of up to ~65 residues while excluding larger, folded proteins.[14][15] It primarily localizes to the mitochondrial matrix, and cuts a range of peptides into recyclable fragments.[16][17] The substrates of PreP are vital to proteostasis, as they can insert to mitochondrial membranes, disrupting electrical potential and uncoupling respiration.[18][19] Thus deletion of PRTRM1 leads to a delayed growth phenotype.[20][21] Notabley, PreP degrades several functionally relevant Aβ species, the aggregates of which are toxic to the neuron and play a key role in AD pathogenesis.[22][14][23]
Clinical significance
PreP is the Aβ-degrading protease in mitochondria. Immune-depletion of PreP in brain mitochondria prevents degradation of mitochondrial Aβ, and PreP activity is found diminished in AD patients.[8] It has been reported that the loss of PreP activity is due to methionine oxidation and this study provides a rational basis for therapeutic intervention in conditions characterized by excessive oxidation of PreP.[24] A recent study also suggests that PreP regulates islet amyloid polypeptide in beta cells.[25] Two siblings carrying a homozygous PITRM1 missense mutation (c.548G>A, p.Arg183Gln) were reported to be associated with an autosomal recessive, slowly progressive syndrome. Clinical features include mental retardation, spinocerebellar ataxia, cognitive decline and psychosis.[26] A mouse model hemizygous for PITRM1 displayed progressive ataxia which was suggested to be linked to brain degenerative lesions, including accumulation of Aβ‐positive amyloid deposits. Recently, two brothers from a consanguineous family presenting with childhood-onset recessive cerebellar pathology were shown to carry a homozygous mutation in PITRM1 (c.2795C>T, p.T931M). This mutation resulted in 95% reduction in PITRM1 protein.[27] PITRM1 knockdown was shown to lead to reduced levels of mature Frataxin protein,[28] a protein that when deficient causes Friedreich's ataxia, and may be implicated in pathology in patients carrying PITRM1 mutations.
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Marusov EV (July 1977). "[Ecological sterotypes of defensive behavior in fish under the action of chemical danger signals]". Nauchnye Doklady Vysshei Shkoly. Biologicheskie Nauki (8): 67–9. PMID1036083.
^Mzhavia N, Berman YL, Qian Y, Yan L, Devi LA (May 1999). "Cloning, expression, and characterization of human metalloprotease 1: a novel member of the pitrilysin family of metalloendoproteases". DNA and Cell Biology. 18 (5): 369–80. doi:10.1089/104454999315268. PMID10360838.
^Alikhani N, Berglund AK, Engmann T, Spånning E, Vögtle FN, Pavlov P, et al. (July 2011). "Targeting capacity and conservation of PreP homologues localization in mitochondria of different species". Journal of Molecular Biology. 410 (3): 400–10. doi:10.1016/j.jmb.2011.05.009. PMID21621546.
^Koppen M, Langer T (2007). "Protein degradation within mitochondria: versatile activities of AAA proteases and other peptidases". Critical Reviews in Biochemistry and Molecular Biology. 42 (3): 221–42. doi:10.1080/10409230701380452. PMID17562452. S2CID6819247.
^Pinho CM, Björk BF, Alikhani N, Bäckman HG, Eneqvist T, Fratiglioni L, et al. (January 2010). "Genetic and biochemical studies of SNPs of the mitochondrial A beta-degrading protease, hPreP". Neuroscience Letters. 469 (2): 204–8. doi:10.1016/j.neulet.2009.11.075. PMID19962426. S2CID31073898.
Schaeffer HJ, Catling AD, Eblen ST, Collier LS, Krauss A, Weber MJ (September 1998). "MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade". Science. 281 (5383): 1668–71. Bibcode:1998Sci...281.1668S. doi:10.1126/science.281.5383.1668. PMID9733512.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (October 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID9373149.
Maruyama K, Sugano S (January 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
